

Rajal B Shah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7573834/publications.pdf>

Version: 2024-02-01

122
papers

18,096
citations

22153

59
h-index

20961

115
g-index

125
all docs

125
docs citations

125
times ranked

16105
citing authors

#	ARTICLE	IF	CITATIONS
1	Renal Cell Carcinoma With Fibromyomatous Stromaâ€”The Whole Story. <i>Advances in Anatomic Pathology</i> , 2022, 29, 168-177.	4.3	17
2	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 461-493.	2.5	143
3	Significant reduction of indeterminate (atypical) diagnosis after implementation of The Paris System for Reporting Urinary Cytology: A singleâ€”institution study of more than 27,000 cases. <i>Cancer Cytopathology</i> , 2021, 129, 114-120.	2.4	8
4	2019 Gleason grading recommendations from ISUP and GUPS: broadly concordant but with significant differences. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 813-815.	2.8	5
5	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1167-1184.	5.5	118
6	Gleason Grade Group Concordance between Preoperative Targeted Biopsy and Radical Prostatectomy Histopathologic Analysis: A Comparison Between In-Bore MRI-guided and MRIâ€”Transrectal US Fusion Prostate Biopsies. <i>Radiology Imaging Cancer</i> , 2021, 3, e200123.	1.6	12
7	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1392-1424.	5.5	138
8	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. <i>Advances in Anatomic Pathology</i> , 2021, 28, 196-208.	4.3	20
9	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. <i>Advances in Anatomic Pathology</i> , 2021, 28, 179-195.	4.3	23
10	Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. <i>American Journal of Cancer Research</i> , 2021, 11, 3990-4001.	1.4	4
11	â€œRenal Cell Carcinoma With Leiomyomatous Stromaâ€”Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity. <i>American Journal of Surgical Pathology</i> , 2020, 44, 571-581.	3.7	67
12	Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate. <i>American Journal of Surgical Pathology</i> , 2020, 44, 673-680.	3.7	31
13	Urothelial Carcinomas With Trophoblastic Differentiation, Including Choriocarcinoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1322-1330.	3.7	15
14	Molecular Biology of Prostate Cancer and Role of Genomic Testing in Diagnosis and Prognosis of Prostate Cancer. , 2019, , 171-180.		0
15	Immunohistochemistry in Prostate Biopsy Evaluation. , 2019, , 33-43.		0
16	Contemporary Approach to Gleason Grading of Prostate Cancer. , 2019, , 45-67.		0
17	Benign Mimics of Prostate Carcinoma. , 2019, , 97-125.		0
18	Intraductal Carcinoma of the Prostate (IDC-P) and Atypical Intraductal Proliferation (AIP). , 2019, , 127-132.		0

#	ARTICLE	IF	CITATIONS
19	PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromagenic carcinoma). <i>Prostate</i> , 2019, 79, 1267-1273.	2.3	34
20	Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes. <i>Histopathology</i> , 2019, 75, 346-353.	2.9	22
21	Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy. <i>Oncogene</i> , 2019, 38, 4496-4511.	5.9	8
22	Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate. <i>American Journal of Surgical Pathology</i> , 2017, 41, 550-556.	3.7	38
23	Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of intraductal carcinoma. <i>Histopathology</i> , 2017, 71, 693-702.	2.9	39
24	<scp>GATA</scp>3 expression in benign prostate glands with radiation atypia: a diagnostic pitfall. <i>Histopathology</i> , 2017, 71, 150-155.	2.9	13
25	Reply to "Low-grade intraductal carcinoma of the prostate: an idea whose time has not yet come": evidence-based medicine suggests that the time is now. <i>Histopathology</i> , 2017, 71, 839-840.	2.9	2
26	HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. <i>Cancer Research</i> , 2017, 77, 74-85.	0.9	137
27	Recent advances in prostate cancer pathology: Gleason grading and beyond. <i>Pathology International</i> , 2016, 66, 260-272.	1.3	28
28	Improvement of diagnostic agreement among pathologists in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies using a novel "Disease-Focused Diagnostic Review" quality improvement process. <i>Human Pathology</i> , 2016, 56, 155-162.	2.0	16
29	ERG overexpression and multifocality predict prostate cancer in subsequent biopsy for patients with high-grade prostatic intraepithelial neoplasia. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 120.e1-120.e7.	1.6	8
30	Diagnosis of Gleason Pattern 5 Prostate Adenocarcinoma on Core Needle Biopsy. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1242-1249.	3.7	43
31	Diagnosis of "Poorly Formed Glands" Gleason Pattern 4 Prostatic Adenocarcinoma on Needle Biopsy. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1331-1339.	3.7	67
32	Utility of PTEN and ERG Immunostaining for Distinguishing High-grade PIN From Intraductal Carcinoma of the Prostate on Needle Biopsy. <i>American Journal of Surgical Pathology</i> , 2015, 39, 169-178.	3.7	99
33	Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling. <i>Human Pathology</i> , 2015, 46, 698-706.	2.0	45
34	Primary Anal Canal Syphilis in Men: The Clinicopathologic Spectrum of an Easily Overlooked Diagnosis. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 1156-1160.	2.5	45
35	New Molecular Markers of Diagnosis and Prognosis in Prostate Cancer. , 2015, , 123-143.		0
36	Signaling mechanisms coupled to CXCL12/CXCR4-mediated cellular proliferation are PTEN-dependent. <i>American Journal of Clinical and Experimental Urology</i> , 2015, 3, 91-9.	0.4	9

#	ARTICLE	IF	CITATIONS
37	Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. <i>Annals of Diagnostic Pathology</i> , 2014, 18, 333-342.	1.3	41
38	Adenocarcinoma of the prostate with Gleason pattern 5 on core biopsy: frequency of diagnosis, morphologic subpatterns, and relation to pattern distribution based on the modified Gleason grading system. <i>Human Pathology</i> , 2014, 45, 2263-2269.	2.0	15
39	The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and 1±-methylacyl-CoA-racemase markers. <i>Human Pathology</i> , 2013, 44, 786-794.	2.0	42
40	Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: Impact of mandatory central pathology review at a large referral hospital. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1650-1655.	1.6	136
41	Clinical Applications of Novel ERG Immunohistochemistry in Prostate Cancer Diagnosis and Management. <i>Advances in Anatomic Pathology</i> , 2013, 20, 117-124.	4.3	44
42	Introducing Parametric Fusion PET/MRI of Primary Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2012, 53, 546-551.	5.0	72
43	Atypical Cribriform Lesions of the Prostate. <i>Advances in Anatomic Pathology</i> , 2012, 19, 270-278.	4.3	44
44	Carcinoma of the Collecting Ducts of Bellini and Renal Medullary Carcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1265-1278.	3.7	127
45	p63, CK7, PAX8 and INI1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system. <i>Histopathology</i> , 2012, 60, 597-608.	2.9	63
46	Lymphoepithelioma-like Carcinoma of the Urinary Bladder. <i>American Journal of Surgical Pathology</i> , 2011, 35, 474-483.	3.7	88
47	Cluster analysis of immunohistochemical profiles delineates CK7, vimentin, S100A1 and CK17 (CD117) as an optimal panel in the differential diagnosis of renal oncocytoma from its mimics. <i>Histopathology</i> , 2011, 58, 169-179.	2.9	51
48	Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 3924-3932.	7.0	69
49	Interobserver Reproducibility in the Diagnosis of Invasive Micropapillary Carcinoma of the Urinary Tract Among Urologic Pathologists. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1367-1376.	3.7	111
50	Atypical Cribriform Lesions of the Prostate: Relationship to Prostatic Carcinoma and Implication for Diagnosis in Prostate Biopsies. <i>American Journal of Surgical Pathology</i> , 2010, 34, 470-477.	3.7	80
51	ETS Gene Aberrations in Atypical Cribriform Lesions of the Prostate. <i>American Journal of Surgical Pathology</i> , 2010, 34, 478-485.	3.7	91
52	Localized Amyloidosis of the Upper Urinary Tract: A Case Series of Three Patients Managed with Reconstructive Surgery or Surveillance. <i>Journal of Endourology</i> , 2010, 24, 641-644.	2.1	17
53	Renal Metastasis from Hurthle Cell Thyroid Carcinoma and Its Evaluation with Hybrid Imaging. <i>Thyroid</i> , 2010, 20, 429-433.	4.5	16
54	Validation of Automatic Target Volume Definition as Demonstrated for 11C-Choline PET/CT of Human Prostate Cancer Using Multi-modality Fusion Techniques. <i>Academic Radiology</i> , 2010, 17, 614-623.	2.5	33

#	ARTICLE	IF	CITATIONS
55	Is residual neurovascular tissue on prostatectomy specimens associated with surgeon intent at nerve-sparing and postoperative quality of life measures?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 487-491.	1.6	17
56	Detection of Aggressive Primary Prostate Cancer with ¹¹ C-Choline PET/CT Using Multimodality Fusion Techniques. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1585-1593.	5.0	86
57	Prevalence of <i>TMPRSS2-ERG</i> Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States. <i>Clinical Cancer Research</i> , 2009, 15, 4706-4711.	7.0	205
58	Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. <i>Modern Pathology</i> , 2009, 22, 1083-1093.	5.5	209
59	Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. <i>Modern Pathology</i> , 2009, 22, 1176-1185.	5.5	91
60	Tomlins et al. reply. <i>Nature</i> , 2009, 457, E2-E3.	27.8	6
61	Benign Diseases and Neoplasms of the Penis. <i>Surgical Pathology Clinics</i> , 2009, 2, 161-197.	1.7	2
62	Nephron-Sparing Diagnosis and Management of Renal Keratinizing Desquamative Squamous Metaplasia. <i>Journal of Endourology</i> , 2009, 23, 51-56.	2.1	8
63	The Discovery of Common Recurrent Transmembrane Protease Serine 2 (TMPRSS2)-Erythroblastosis Virus E26 Transforming Sequence (ETS) Gene Fusions in Prostate Cancer. <i>Advances in Anatomic Pathology</i> , 2009, 16, 145-153.	4.3	47
64	Renal Tubulocystic Carcinoma Is Closely Related to Papillary Renal Cell Carcinoma: Implications for Pathologic Classification. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1840-1849.	3.7	121
65	Current Perspectives on the Gleason Grading of Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 1810-1816.	2.5	40
66	Dkkopfa ϵ 1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. <i>Prostate</i> , 2008, 68, 1396-1404.	2.3	127
67	The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers. <i>Cancer Cell</i> , 2008, 13, 519-528.	16.8	303
68	Registration Methodology for Histological Sections and In Vivo Imaging of Human Prostate. <i>Academic Radiology</i> , 2008, 15, 1027-1039.	2.5	92
69	Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer. <i>Neoplasia</i> , 2008, 10, 177-IN9.	5.3	608
70	Characterization of <i>TMPRSS2</i> -ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer. <i>Cancer Research</i> , 2008, 68, 3584-3590.	0.9	249
71	A Fluorescence <i>In situ</i> Hybridization Screen for E26 Transformation ϵ Specific Aberrations: Identification of DDX5-ETV4 Fusion Protein in Prostate Cancer. <i>Cancer Research</i> , 2008, 68, 7629-7637.	0.9	139
72	Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3933-3938.	7.1	641

#	ARTICLE	IF	CITATIONS
73	Characterization of <i>TMPRSS2-ERG</i> Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications. <i>Clinical Cancer Research</i> , 2008, 14, 3380-3385.	7.0	200
74	Renal Cell Carcinomas With Papillary Architecture and Clear Cell Components. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1780-1786.	3.7	98
75	Tubulocystic Carcinoma of the Kidney. <i>American Journal of Surgical Pathology</i> , 2008, 32, 177-187.	3.7	156
76	Clear Cell Papillary Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1239-1245.	3.7	252
77	Partial Atrophy in Prostate Needle Biopsies: A Detailed Analysis of Its Morphology, Immunophenotype, and Cellular Kinetics. <i>American Journal of Surgical Pathology</i> , 2008, 32, 58-64.	3.7	39
78	Integrating Biomedical Knowledge to Model Pathways of Prostate Cancer Progression. <i>Cell Cycle</i> , 2007, 6, 1177-1187.	2.6	12
79	A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome. <i>Cancer Research</i> , 2007, 67, 10657-10663.	0.9	308
80	Integrative Analysis of Genomic Aberrations Associated with Prostate Cancer Progression. <i>Cancer Research</i> , 2007, 67, 8229-8239.	0.9	103
81	Variable Penetrance of a Consensus Classification Scheme for Renal Cell Carcinoma. <i>Urology</i> , 2007, 69, 452-456.	1.0	5
82	Percent Positive Biopsy Cores as a Prognostic Factor for Prostate Cancer Treated with External Beam Radiation. <i>Urology</i> , 2007, 69, 936-940.	1.0	37
83	Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: Defining risk with prostate capsule sparing cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 460-464.	1.6	26
84	Heterogeneity of <i>TMPRSS2</i> Gene Rearrangements in Multifocal Prostate Adenocarcinoma: Molecular Evidence for an Independent Group of Diseases. <i>Cancer Research</i> , 2007, 67, 7991-7995.	0.9	197
85	The quality of surgical pathology care for men undergoing radical prostatectomy in the U.S.. <i>Cancer</i> , 2007, 109, 2445-2453.	4.1	11
86	Integrative molecular concept modeling of prostate cancer progression. <i>Nature Genetics</i> , 2007, 39, 41-51.	21.4	837
87	Comprehensive assessment of <i>TMPRSS2</i> and ETS family gene aberrations in clinically localized prostate cancer. <i>Modern Pathology</i> , 2007, 20, 538-544.	5.5	281
88	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. <i>Nature</i> , 2007, 448, 595-599.	27.8	743
89	Integrative Genomics Analysis Reveals Silencing of β^2 -Adrenergic Signaling by Polycomb in Prostate Cancer. <i>Cancer Cell</i> , 2007, 12, 419-431.	16.8	204
90	Noninvasive Detection of <i>TMPRSS2:ERG</i> Fusion Transcripts in the Urine of Men with Prostate Cancer. <i>Neoplasia</i> , 2006, 8, 885-888.	5.3	212

#	ARTICLE	IF	CITATIONS
91	Whole Transcriptome Amplification for Gene Expression Profiling and Development of Molecular Archives. <i>Neoplasia</i> , 2006, 8, 153-162.	5.3	40
92	TMPRSS2:ETV4 Gene Fusions Define a Third Molecular Subtype of Prostate Cancer. <i>Cancer Research</i> , 2006, 66, 3396-3400.	0.9	432
93	A Working Group Classification of Focal Prostate Atrophy Lesions. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1281-1291.	3.7	123
94	Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. <i>Prostate</i> , 2006, 66, 248-256.	2.3	197
95	Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: Correlation with androgen independence. <i>Prostate</i> , 2006, 66, 1437-1444.	2.3	74
96	Prostate-Specific Antigen, High-Molecular-Weight Cytokeratin (Clone 34 β E12), and/or p63. <i>American Journal of Clinical Pathology</i> , 2006, 125, 675-681.	0.7	85
97	Recurrent Fusion of <i>TMPPRSS2</i> and ETS Transcription Factor Genes in Prostate Cancer. <i>Science</i> , 2005, 310, 644-648.	12.6	3,541
98	CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. <i>Aging Cell</i> , 2005, 4, 291-298.	6.7	110
99	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. <i>Cancer Cell</i> , 2005, 8, 393-406.	16.8	731
100	Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia. <i>Pathology International</i> , 2005, 55, 248-254.	1.3	60
101	MDCT Urography of Upper Tract Urothelial Neoplasms. <i>American Journal of Roentgenology</i> , 2005, 184, 1873-1881.	2.2	184
102	Laparoscopic and Open Surgical Nephrectomy for Xanthogranulomatous Pyelonephritis. <i>Journal of Endourology</i> , 2005, 19, 813-817.	2.1	35
103	Image-guided biopsy in the evaluation of renal mass lesions in contemporary urological practice: indications, adequacy, clinical impact, and limitations of the pathological diagnosis. <i>Human Pathology</i> , 2005, 36, 1309-15.	2.0	31
104	MRI for Preoperative Staging of Renal Cell Carcinoma Using the 1997 TNM Classification: Comparison with Surgical and Pathologic Staging. <i>American Journal of Roentgenology</i> , 2004, 182, 217-225.	2.2	77
105	Usefulness of Basal Cell Cocktail (34 β E12 + p63) in the Diagnosis of Atypical Prostate Glandular Proliferations. <i>American Journal of Clinical Pathology</i> , 2004, 122, 517-523.	0.7	82
106	Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases. <i>Cancer Research</i> , 2004, 64, 9209-9216.	0.9	816
107	Detection and expression of human BK virus sequences in neoplastic prostate tissues. <i>Oncogene</i> , 2004, 23, 7031-7046.	5.9	76
108	Elevated β -Methylacetyl-CoA Racemase Enzymatic Activity in Prostate Cancer. <i>American Journal of Pathology</i> , 2004, 164, 787-793.	3.8	68

#	ARTICLE	IF	CITATIONS
109	Usefulness of Basal Cell Cocktail (p63+34bE12) in the Diagnosis of Atypical Prostate Glandular Proliferations. American Journal of Clinical Pathology, 2004, 122, 517-523.	0.7	29
110	Diagnostic Usefulness of Monoclonal Antibody P504S in the Workup of Atypical Prostatic Glandular Proliferations. American Journal of Clinical Pathology, 2003, 120, 737-745.	0.7	64
111	Basal Cell Cocktail (34bE12 + p63) Improves the Detection of Prostate Basal Cells. American Journal of Surgical Pathology, 2003, 27, 365-371.	3.7	141
112	Diagnostic Usefulness of Monoclonal Antibody P504S in the Workup of Atypical Prostatic Glandular Proliferations. American Journal of Clinical Pathology, 2003, 120, 737-745.	0.7	9
113	In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biology and Therapy, 2003, 2, 656-60.	3.4	28
114	Comparison of the Basal Cell-Specific Markers, 34bE12 and p63, in the Diagnosis of Prostate Cancer. American Journal of Surgical Pathology, 2002, 26, 1161-1168.	3.7	175
115	HLA-DR and HLA-DQ polymorphism in human thyroglobulin-induced autoimmune thyroiditis: DR3 and DQ8 transgenic mice are susceptible. Human Immunology, 2002, 63, 301-310.	2.4	25
116	Isolated recurrent renal cell carcinoma metastatic to the bladder. Journal of the National Medical Association, 2002, 94, 912-4.	0.8	5
117	Postatrophic Hyperplasia of the Prostate Gland. American Journal of Pathology, 2001, 158, 1767-1773.	3.8	125
118	Delineation of prognostic biomarkers in prostate cancer. Nature, 2001, 412, 822-826.	27.8	1,551
119	Histologic and Histochemical Characterization of Seminal Vesicle Intraluminal Secretions. Archives of Pathology and Laboratory Medicine, 2001, 125, 141-145.	2.5	9
120	Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors. Urology, 2000, 56, 721-725.	1.0	44
121	H2-E transgenic class II-negative mice can distinguish self from nonself in susceptibility to heterologous thyroglobulins in autoimmune thyroiditis. Immunogenetics, 1999, 50, 22-30.	2.4	17
122	Enrichment of "Cribriform" morphologies (intraductal and cribriform adenocarcinoma) and genomic alterations in radiorecurrent prostate cancer. Modern Pathology, 0, , .	5.5	3